Surmodics Reports Third Quarter Fiscal 2019 Results and Raises Fiscal 2019 Revenue and EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
SurModics (SRDX) Tops Q3 EPS by 10c, Revenues Beat; Raises FY19 EPS/Revenue Guidance Above Consensus
July 31, 2019 5:53 PM EDTSurModics (NASDAQ: SRDX) reported Q3 EPS of $0.15, $0.10 better than the analyst estimate of $0.05. Revenue for the quarter came in at $24.3 million versus the consensus estimate of $22.29 million.
Summary of Third Quarter and Recent Highlights
Revenue of $24.3 million, an increase of 9.5% year-over-yearGAAP EPS of $0.11, non-GAAP EPS of $0.15TRANSCEND clinical trial enrollment more than 90% completeOur third... More
